China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Strong Overseas Efficacy Data
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
You may also be interested in...
The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.